IOL Chemicals and Pharmaceuticals Limited
NSE: IOLCPMarket Closed • NSE
Day range
52 week range
IOL Chemicals and Pharmaceuticals Limited closed at INR194.69 (-0.2%) on volume 0.63x its 20-day average, trading 13.08% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +21.1% QoQ
2026-02-17
DIVIDEND Announced
Interim Dividend - Re 1 Per Share
2025-03-11
DIVIDEND Announced
Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.08x
High Cash Flow Conversion: CFO/PAT averaged 1.65x over last 3 years
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 17 Feb 2026 | Dividend | ₹1.00 / share | — | 17 Feb 2026 |
| 11 Mar 2025 | Dividend | ₹10.00 / share | — | 11 Mar 2025 |
| 18 Feb 2025 | Dividend | ₹4.00 / share | — | 18 Feb 2025 |
| — | Annual General Meeting | Annual General Meeting | — | 16 Aug 2024 |
| 16 Feb 2024 | Dividend | ₹5.00 / share | — | 16 Feb 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 03 Aug 2023 |
| 17 Feb 2023 | Dividend | ₹4.00 / share | — | 17 Feb 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 18 Aug 2022 |
| 16 Feb 2022 | Dividend | ₹4.00 / share | — | 15 Feb 2022 |
| — | Dividend | ₹2.00 / share | — | 08 Sept 2021 |
| 18 Nov 2020 | Dividend | ₹4.00 / share | — | 17 Nov 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 17 Sept 2020 |
| 19 Mar 2020 | Dividend | ₹3.00 / share | — | 18 Mar 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 21 Aug 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 19 Sept 2018 |
| — | Annual General Meeting | Annual General Meeting | — | 19 Sept 2017 |
| — | Annual General Meeting | Annual General Meeting | — | 19 Sept 2016 |
| — | Annual General Meeting | Annual General Meeting | — | 18 Sept 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. The company operates through, Chemical and Pharmaceutical segments. The Chemical segment offers ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, and acetic anhydride to food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and chemical intermediates industries. The Pharmaceutical segment provides active pharmaceutical ingredients, such as ibuprofen, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, and paracetamol. Its active pharmaceutical ingredients are used for the treatment of anti-inflammatory, analgesic and antipyretic, anti-diabetic, anti- platelet, anti-cholesterol, anti- convulsant, anti-epileptic, anti-hypertensive, and anti-cholelithic, as well as proton pump inhibitor. IOL Chemicals and Pharmaceuticals Limited was incorporated in 1986 and is based in Ludhiana, India.
IndiaHealthcare
Is IOL Chemicals and Pharmaceuticals Limited Shariah compliant?
IOL Chemicals and Pharmaceuticals Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (2.37%) complies with AAOIFI threshold (≤ 33%).
What is IOL Chemicals and Pharmaceuticals Limited's current valuation relative to peers?
IOL Chemicals and Pharmaceuticals Limited trades at a P/E of 34.0x compared to the sector median of 37x, and a Price-to-Book of 3.2x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.08x. Interest coverage is 13x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 1.8% while net profit growth averaged 0.5%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.